Lead Product(s) : Osavampator
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Neurocrine Starts Phase 3 Osavampator Trial for Depression
Details : NBI-1065845 (osavampator) is an investigational AMPA positive allosteric modulator. It is being evaluated for the treatment of adults with major depressive disorder.
Product Name : NBI-1065845
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Osavampator
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable